We are thrilled to announce that Glenn Schulman has joined ProKidney Corp. as its SVP, Investor Relations. Click on the press release to learn more. investors.prokidney.com/news-releases/…

Join $PROK for a #FiresideChat at the Morgan Stanley Healthcare Conference next week. Tune in to the live webcast 9/14 at 11:10 a.m. ET or replay at bit.ly/PROKEvents. Press release at bit.ly/3RPN26u

$PROK has received the allowances from UK’s MHRA MHRAgovuk for #proact1 (REGEN-006) Phase 3 study and scientific advice from the EMA EU Medicines Agency for our investigational candidate #REACT program! Read the full release here: shorturl.at/HKMY2

ProKidney reports third quarter 2022 financial results and recent operational highlights. View the news release here: tinyurl.com/muf5vy46

Join $PROK for a #FiresideChat at the Jefferies London Healthcare Conference this Wednesday! Tune in to the live webcast on Nov. 16 at 7:20 AM ET here: tinyurl.com/mtz6kt8h

Join $PROK for a #FiresideChat at the Evercore ISI Healthcare Conference this Thursday. Tune in to the live webcast on Dec. 1 at 10:05 AM ET here: tinyurl.com/mtz6kt8h

#ICYMI: ProKidney was recently featured in BioSpace! Dr. Tim Bertram, ProKidney’s CEO, discussed REACT®, REnal Autologous Cell Therapy, currently in Phase 3 and had recently presented preclinical data at this year’s American Society of Nephrology conference. Read here: tinyurl.com/4cbm7w55

$PROK will present at the BofA Securities 2023 Health Care Conference in Las Vegas, NV on Tuesday, May 9, 2023, at 4:20 PM PDT (7:20 PM EDT). Read the full release here: tinyurl.com/ys95ur3x #bofasecurities

$PROK reports first quarter 2023 financial results and recent corporate highlights. Read the full release here: tinyurl.com/4p9ntkhs

Join $PROK for a #FiresideChat at the Jefferies Healthcare Conference on June 7 – 9, 2023. Tune into the live webcast on Thursday, June 8, at 4:00 p.m. ET or replay here: tinyurl.com/3kms4xts

$PROK is pleased to announce the appointment of Bruce Culleton, MD, as Executive Vice President, Clinical Development and Commercialization! Read the full release here: tinyurl.com/ynnn4fkd

$PROK reports second quarter 2023 financial results and recent corporate highlights. Read the full release here: tinyurl.com/5bbmtfkp

Join $PROK for a #FiresideChat at the 2023 Morgan Stanley Global Healthcare Conference on September 11 – 14, 2023. Tune into the live webcast on Monday, Sept. 11 at 12:15 p.m. ET or replay here: tinyurl.com/3kms4xts

$PROK will be presenting at American Society of Nephrology’s Kidney Week 2023 on November 2-5, 2023, in Philadelphia, PA! Visit PROK’s booth #938 during exhibit hours! For more details, read the full release here: tinyurl.com/3pmwktvm #KidneyWk #ASN

We’re heading to the Jefferies Biotech on the Bay Summit in Miami on March 12, 2024. The ProKidney management team looks forward to hosting one-on-one meetings. For additional details, please read our full press release here: investors.prokidney.com/news-releases/…

We are proud to support World Kidney Day in their mission and will continue to work towards supporting continued innovation in the #CKD treatment landscape. Learn more about ProKidney’s program here: prokidney.com #WorldKidneyDay2024 #KidneyHealth

Today we announced key leadership appointments strengthening clinical and technical operations. Read the full press release here: investors.prokidney.com/news-releases/…

Join ProKidney Corp. ($PROK) for a virtual KOL event on Tues. May 28 at 8am ET featuring Steven G. Coca, DO, MS and Arnold L. Silva, MD, PhD who will discuss the current treatment landscape for patients with moderate to severe #CKD caused by diabetes. Register: bit.ly/3yo8xqr

Don't miss it! ProKidney Corp. ($PROK) is hosting a virtual KOL event on May 28 at 8am ET with Steven G. Coca, DO, MS and Arnold L. Silva, MD, PhD to discuss the current treatment landscape for patients with moderate to severe #CKD caused by diabetes. Register: bit.ly/3yo8xqr

We announced the pricing of our upsized $130 million public offering to support the continued development of rilparencel, our Phase 3 candidate being evaluated to potentially preserve kidney function in diabetic patients at high risk of kidney failure. bit.ly/4ch86Nd